Welgene Biotech Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 at 06:28 pm EST
Share
Welgene Biotech Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 72.2 million compared to TWD 82.63 million a year ago. Net income was TWD 4.71 million compared to net loss of TWD 0.103 million a year ago. Basic earnings per share from continuing operations was TWD 0.2. Diluted earnings per share from continuing operations was TWD 0.2. Basic earnings per share was TWD 0.2. Diluted earnings per share was TWD 0.2.
For the nine months, sales was TWD 249.62 million compared to TWD 206.45 million a year ago. Net income was TWD 12.11 million compared to TWD 0.139 million a year ago. Basic earnings per share from continuing operations was TWD 0.52 compared to TWD 0.01 a year ago. Diluted earnings per share from continuing operations was TWD 0.52 compared to TWD 0.01 a year ago. Basic earnings per share was TWD 0.52 compared to TWD 0.01 a year ago. Diluted earnings per share was TWD 0.52 compared to TWD 0.01 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
